PRYTEK
23.7.2021 03:02:11 CEST | Business Wire | Press release
Aligned with Prytek’s strategy on building technologies and delivering managed services, it is building a new software testing arm by merging its own Technological company prooV™ with QAssure, a leading Asia based software testing company. After the merger Prytek will be the major shareholder providing software testing and prooV™ of Concept as a Service to the global market. Prytek is leading with the concept of BOPaaS (Business Operating Platform as Service) where it is lifting out entire operations from corporates providing them an entire operational solution based on Prytek technologies. The group operated in several sectors such as Financial Services, Cyber & Tech Education and HR sectors. This concept helps CEOs focus on their core business and outsource all banking regulations, software, and education requirements to Prytek.
QAssure and prooV™ announced their agreement to merge under the name of QAssure with Durairaj Dhanasekaran as its CEO. QAssure market-leading testing company head quartered in Singapore with a continuous testing technology platform and managed service capability. prooV™ owned by Prytek, is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. The combined services represent the most modern platform for accelerating open innovation and transforming software testing to keep pace with digital transformation. The combined entity will have a global presence with offices in Asia, the US, and EMEA. This integration will reflect the commitment to innovation and customer success that both companies share.
Andrey Yashunsky CEO of Prytek says “With this merger, we are creating deep tech proof of concept and digital assurance platform company that help accelerate and fast-track open innovation. With a strong implementation support centre based in Singapore, an R&D team based out of Israel and an offshore development team based out of India, we will be able to bring the best minds to build and deliver great technology and services addressing the global customer needs.”
Toby Olshanetsky, CEO and co-founder of prooV™ adds "We are very excited with this merger, in prooV™ we created the first PoC as a Service platform and now we create the first full end to end solution for technology & innovation adoption, using prooV™ and QAssure we provide a 360 offering: before, during and after the POC, enterprises can assess and test multiple technologies simultaneously to identify feature sets, scaling challenges, performance bottlenecks, and security risks before releasing an application to production".
According to Technavio, the global software testing services market has the potential to grow by USD 34.49 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 12.39%. Enterprises have started focusing more on Quality Assurance, which can be gained by the implementation of agile solutions, leading to significant investments for the advancement of the latest quality assurance & software testing services.
About QAssure:
QAssure Technologies is an Independent Software Testing Company founded in 2005. Headquartered in Singapore with an expanding presence in India, Malaysia, Indonesia and the USA, QAssure Technologies focuses on specialized QA Engineering and Testing services with continuous autonomous validation and verification platform. QAssure Technologies brings together the essential combinations of value-driven robust domain knowledge, platforms and exceptional technical capabilities and burgeoning strategic alliances for leading IT solutions. Our expanding global footprint makes it possible for us to meet the software testing demands with versatile delivery models and specialized resources.
About Proov:
prooV™ is the first and only end-to-end proof-of-concept platform for third-party software, enabling global enterprises to evaluate and adopt the right new technologies safely, at a fraction of the time and cost. prooV consolidates the PoC process into one end-to-end ecosystem. With its simplified configuration and single point of integration, prooV enables companies to complete PoCs within days, not months, to run multiple PoCs simultaneously and to quickly evaluate different technology solutions from pre-screened vendors. prooV is the must-have solution for any organization looking to fast-track innovation.
About Prytek:
Prytek is a multinational technology group that builds deep technology and SaaS solutions through a BOPaaS (Business Operating Platform-as-a-Service) which is a combination of Deep Tech Solutions with Managed Services and Capital, providing the capability to lift out entire operations to create more efficient businesses of the future. Headed by industry experts, Prytek builds businesses and ecosystems in the Financial Services, Cyber & Tech Education and HR sectors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005855/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom